Biosimilar Switching: What Happens When You Change from Originator

When you switch from an originator biologic to a biosimilar, you’re not just changing the brand name on the bottle. You’re stepping into a medical shift backed by science, but shaped by perception. Many patients wonder: Will my treatment still work? Will I feel different? Is this safe? The answer isn’t simple - and that’s okay. Let’s break down what actually happens when this switch occurs.

What Exactly Is a Biosimilar?

A biosimilar isn’t a generic drug. Generics copy small-molecule pills - think aspirin or statins - with identical chemical structures. Biologics are different. They’re made from living cells, not chemicals. That means they’re complex, fragile, and hard to replicate exactly. A biosimilar doesn’t need to be identical. It just needs to be highly similar in structure, function, and effect. Regulatory agencies like the FDA and EMA require over 250 analytical tests to prove this. Think of it like two handmade wooden chairs: they look nearly the same, use the same wood, and hold the same weight. But one might have a slightly different stain. That’s a biosimilar.

The first biosimilar approved in the U.S. was Zarxio (filgrastim-sndz) in 2015. Since then, 37 have been approved, mostly for conditions like rheumatoid arthritis, Crohn’s disease, and psoriasis. These drugs target inflammation by blocking proteins like TNF-alpha. The most common switches involve infliximab and adalimumab - two of the most widely used biologics.

What Happens When You Switch?

Switching usually happens for one of two reasons: cost or policy. Health systems want to save money. Originator biologics can cost over $20,000 a year. Biosimilars cost 15-35% less. In 2023, Humira biosimilars launched at 35% off in the U.S. That’s billions saved across insurance plans. Some insurers now require you to switch - it’s called a non-medical switch. Others let your doctor decide - that’s a medical switch.

Here’s what clinical studies show:

• After switching from originator infliximab to its biosimilar CT-P13, 52.6% of patients stayed on treatment after one year - compared to 60% who stayed on the original. That difference wasn’t statistically significant.
• In psoriasis patients switching from adalimumab to a biosimilar, 79% kept using the drug after a year. Before the switch, it was 81.3%.
• A study tracking patients through two switches - originator to biosimilar, then biosimilar to another biosimilar - found no meaningful rise in side effects or loss of effectiveness.

What does this mean? For most people, switching doesn’t break the treatment. Disease activity stays stable. Lab markers like drug levels and inflammation indicators (like fecal calprotectin in IBD or DAS28 in arthritis) stay within normal ranges.

Why Do Some People Stop Taking It?

Not everyone stays. Around 4-18% of patients stop after a switch. But here’s the twist: most of them aren’t getting worse. They just feel worse.

Psychology plays a big role. This is called the nocebo effect - the opposite of placebo. If you believe a change will hurt you, your body might respond as if it did. A 2021 study found 32.7% of patients reported new symptoms after switching, even though their bloodwork showed no change. Reddit threads from patients with rheumatoid arthritis are full of posts like: “I switched and my knees started aching again.” But when doctors checked, their inflammation scores hadn’t moved.

Real side effects do happen - but rarely. Injection site reactions, headaches, or mild fatigue occur in about 7-14% of cases. True immune reactions - like developing anti-drug antibodies - are rare: only 1.7 events per 100 patient-years. That’s less than 2% over five years.

One study found that patients who were fully informed before switching had discontinuation rates drop from 18% to just 6.4%. Talking through the process - explaining what biosimilars are, showing data, answering fears - makes a huge difference.

Is Switching Safe Between Biosimilars?

Yes. You can switch from one biosimilar to another. It’s not a gamble. The NOR-SWITCH II study tracked patients who switched twice - originator to biosimilar, then biosimilar to biosimilar - over two years. 89.2% stayed on treatment. Drug levels stayed steady. No spikes in antibodies. No increase in hospital visits.

There’s one exception: some small studies in IBD patients showed slightly higher discontinuation after switching between two biosimilars (CT-P13 to SB2). But even there, drug levels didn’t drop. The reason? Probably not the medicine. It was likely anxiety, misattributed symptoms, or poor communication.

Regulators agree. The EMA says switching between biosimilars is safe. The FDA, which now approves interchangeable biosimilars (like Cyltezo for Humira), allows pharmacists to swap them without asking the doctor - because the science says it’s safe.

What About Long-Term Effects?

There’s no evidence that switching causes long-term harm. Studies tracking patients for up to five years show no increased risk of serious infections, cancer, or death. In fact, a 2023 FDA analysis of over 5,700 patients found no increase in serious side effects after switching.

Some doctors worry about cumulative exposure - switching back and forth multiple times. But data doesn’t support that fear. In one study, patients switched three times over three years. Their disease activity stayed controlled. Their drug levels stayed stable. Their antibody levels didn’t climb.

What does matter is consistency. If you’re stable - your arthritis is quiet, your IBD is in remission - switching is low risk. If you’re flaring, or your disease is unstable, hold off. Don’t switch during a flare. Wait until you’re steady.

Who Should Avoid Switching?

Not everyone should switch. Here are the cases where caution is advised:

• Patients with active, uncontrolled disease (DAS28 > 3.2 for RA, or active Crohn’s symptoms)
• Those who previously lost response to a biologic - switching won’t fix that
• Patients with a history of severe allergic reactions to biologics
• People who’ve had multiple switches already - more switches = more chance for confusion

Also, don’t switch if you’re pregnant or planning to be. Data is limited here. Talk to your doctor.

The Real Cost - Beyond Money

Biosimilars save money. That’s clear. But the real cost? It’s trust.

Patients worry: “Is this cheaper version less good?” The answer is no - but the fear is real. That’s why education matters more than policy. A mandatory switch without counseling leads to higher dropout rates. A shared decision - where you’re involved, informed, and heard - leads to better outcomes.

Health systems in Europe have been switching for over a decade. In Denmark and Norway, over 85% of patients stay on biosimilars after switching. In the U.S., adoption is slower - only 24% of infliximab users are on biosimilars. Why? Patent battles, pharmacy rebates, and lack of patient education.

What Should You Do If You’re Asked to Switch?

If your doctor or insurer says you need to switch, here’s what to do:

1. Ask for the data. Request studies showing safety for your condition.
2. Request a counseling session. At least 20 minutes. Ask: “What will I feel? What should I watch for?”
3. Ask about monitoring. Will your drug levels be checked? Will your symptoms be tracked?
4. Set a 3-month check-in. Don’t assume you’ll feel worse. But don’t ignore changes either.
5. Speak up. If you feel different - even if tests look fine - tell your doctor. It might be nocebo. Or it might be real.

Most people switch without issue. But if you’re one of the few who feel off, you’re not imagining it. You just need the right support.

Final Thought: It’s Not About the Drug - It’s About the Experience

Biosimilar switching isn’t a clinical experiment. It’s a human experience. You’re not a data point. You’re someone managing a chronic illness. You’ve built trust with your treatment. Changing that can feel scary.

The science says: it’s safe. The data says: it works. But the emotional truth? It’s more complicated. That’s why communication, patience, and respect matter more than any policy.

If you’re stable, informed, and supported - switching is a smart choice. For you. For your health. And for the system that helps you get there.